Ramalingam S, Reungwetwattana T, Chewaskulyong B, et al. Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA. ESMO 2017 Congress; abstract LBA2_PR.
Sintilimab bij niet-resectabel adenocarcinoom van de maag of gastro-oesofageale overgang
mrt 2024 | Immuuntherapie, Maag-darm-leveroncologie